25th April 2012

Aurobindo Pharma receives final approval for Olanzapine Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg (ANDA 091388)

Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg are the generic equivalent of Eli Lilly & Company's Zyprexa® Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Olanzapine Tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and falls under the Neurological (CNS) therapeutic category. The annual sale of Olanzapine Tablets is approximately US$3.2 billion and is ready for launch.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

Aurobindo now has a total of 149 ANDA approvals (121 Final approvals including 1 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com